Dosing and concentration
Cagrilintide is experimental. Weekly amounts of 0.3, 0.6, 1.2, 2.4 and 4.5 mg describe different clinical protocols, not a sequence for you to follow. A combination plan must specify each peptide separately.
A statement such as “2.4 mg CagriSema” is incomplete unless it identifies both component amounts. It can be unclear whether someone means cagrilintide, semaglutide or a combined total. The same ambiguity applies to a vial labelled only with a blend name.
For measurement only, 0.1 mL of a documented 3 mg/mL solution contains 0.3 mg. The concentration, not the word “units,” determines the delivered amount. A U-100 syringe measures 0.1 mL at 10 marked units. This example does not select a personal dose or reconstitution recipe.
Preparation and reconstitution
Cagrilintide’s acidity, other ingredients and container affect how the solution behaves. A lyophilised vial needs its own preparation instructions; dissolving it does not reproduce another formulation.
Bacteriostatic water is not compatible with every peptide or mixture. Its preservative does not establish storage life or make contaminated material sterile. Confirm the diluent, final concentration and discard date for the preparation.
Do not mix cagrilintide and semaglutide in one vial or syringe unless the specific formulation instructions permit it. Using two medicines in a plan does not mean their solutions can be combined.
Administration
SubQ means an injection into the fatty layer beneath the skin. It does not mean injecting into the gut or directing fat loss to the injection site. Follow the instructions for the specific preparation and device.
A clean work surface, handwashing, new sterile equipment and a sharps container belong to injection handling. Site rotation helps avoid repeatedly irritating one patch of skin. Avoid bruised, red, hardened or damaged areas and follow the device-specific instructions demonstrated by the clinical team.
A visible droplet or uncertain delivery should be recorded, not automatically corrected with another full injection. Do not share pens, needles or syringes, and do not use oral or topical preparations for injection.
Oral versus subcutaneous delivery
An oral peptide must survive digestion and cross the gut lining. Injection avoids that initial digestive route. A cagrilintide capsule cannot be assumed equivalent to an injection.
Cagrilintide is intended to affect appetite signalling, not to act as a local bowel treatment. Poor oral absorption does not create an anti-inflammatory benefit in the gut.
Half-life
Approximately 6.6–8.1 days for the measured injectable preparation. Doses overlap, and effects do not stop immediately after the last dose.
Storage
Follow the storage instructions for the exact cagrilintide preparation. Semaglutide’s room-temperature allowance does not transfer to cagrilintide, even when both are in the same treatment plan.
For any prepared vial, record the preparation date, concentration and assigned discard date. Keep temperature excursions in the record. Refrigeration cannot establish a missing stability period, and visual clarity cannot rule out contamination or chemical change. Avoid repeated transfer between containers and do not freeze unless the exact instructions require it.
Contraindications and side effects
Possible effects include nausea, constipation, diarrhoea and injection-site reactions. Reduced intake becomes a problem if it causes weakness, dehydration or poor nutrition. Severe abdominal pain or persistent vomiting needs medical assessment.
Pregnancy, breastfeeding, significant stomach-emptying problems, diabetes medicines and other appetite treatments require individual review. Amylin-family pharmacology should prompt careful attention to food intake and glucose management rather than an assumption that every related drug has identical contraindications.
Tell the treating team about new medicines, planned procedures and significant symptoms. Long-term risks and interactions are not fully mapped; an undocumented combination should not be treated as confirmed safe.
Tracking progress and common questions
Record fullness before and after meals, nausea, bowel changes, hydration and the exact peptide or combination. Separate the names and amounts of both components if reviewing a combination plan. Note functional changes and a consistent weight trend.
“Is CagriSema a different name for cagrilintide?” No: it includes semaglutide. “Can I judge the effect after one day?” A long-acting peptide may have a changing response over several weeks. “Should I keep reducing meals because I can?” No: meeting nutritional needs is part of a useful outcome.